www.fdanews.com/articles/179187-illumina-launches-trusight-tumor-170
Illumina Launches TruSight Tumor 170
November 7, 2016
Illumina has launched TruSight Tumor 170, which is a 170 gene sequencing solution to support the evolution of the tumor-profiling paradigm from a series of single-gene tests to a multi-analyte approach.
This assay is designed to support limited nucleic acid input from formalin-fixed, paraffin-embedded samples and facilitates efficient evaluation of biomarkers.
The device will begin production in early 2017. — Cynthia Jessup